BioCaptiva

BioCaptiva is an early-stage diagnostics company developing a novel polymer-based platform, msX™, for the direct capture and stabilization of cfDNA from liquid biopsy samples. The technology addresses key limitations in current liquid biopsy workflows, such as restricted sample volumes, poor sample quality, and complex pre-analytical processing, by enabling high-yield, selective capture from diverse biofluids with room-temperature stability. Backed by a seasoned leadership team with experience in medical devices and biotech, the company is positioning its platform to expand the utility of liquid biopsy in cancer diagnosis, monitoring, and personalized treatment planning. BioCaptiva is currently pre-revenue, focusing on technology development and commercial partnerships.

msX™, a patented suite of polymers for the direct, reagent-free capture and stabilization of cell-free DNA (cfDNA) from biological fluids. The platform selectively binds low molecular weight cfDNA, enables room-temperature sample stability for up to 90 days, and allows processing of unlimited sample volumes in flow-through formats.

BioCaptiva competes in the sample preparation segment of the liquid biopsy market, dominated by large players like Qiagen, Roche, Thermo Fisher Scientific, and numerous kit suppliers. Its differentiation is based on a novel polymer chemistry that eliminates reagents and enables large-volume processing, a claim not made by conventional magnetic bead-based extraction methods. Success depends on proving this technical advantage translates to clear clinical and economic benefits for users.